CSIMarket
 
Adaptive Biotechnologies Corporation  (ADPT)
Other Ticker:  
 
 
Price: $3.2400 $-0.02 -0.613%
Day's High: $3.335 Week Perf: -14.29 %
Day's Low: $ 3.21 30 Day Perf: -17.77 %
Volume (M): 1,751 52 Wk High: $ 9.08
Volume (M$): $ 5,673 52 Wk Avg: $5.82
Open: $3.23 52 Wk Low: $2.61



 Market Capitalization (Millions $) 469
 Shares Outstanding (Millions) 145
 Employees 645
 Revenues (TTM) (Millions $) 180
 Net Income (TTM) (Millions $) -196
 Cash Flow (TTM) (Millions $) -128
 Capital Exp. (TTM) (Millions $) 12

Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a biotechnology company that specializes in the field of immune-driven medicine.
Founded in 2009 by Chad Robins and Harlan Robins, the Seattle-based company is focused on developing procedures and technologies to decode the immune system to help diagnose, manage, and treat various diseases.
Adaptive Biotechnologies' flagship product is its immune profiling technology, which uses next-generation sequencing and machine learning algorithms to read the genetic makeup of a patient's immune system.
This technology allows the company to develop highly personalized, targeted therapies for various types of cancers and autoimmune disorders.
The company has built a proprietary database of immune system data that is the largest and most diverse in the world.
This database is continuously growing through partnerships with biopharmaceutical companies and academic institutions.
Adaptive Biotechnologies also collaborates with researchers and physicians around the globe to advance the understanding of the immune system and develop new therapies.
Adaptive Biotechnologies has partnered with many pharmaceutical and biotech companies, such as Genentech and Amgen, to develop new diagnostic and therapeutic products.
The company has also received funding and investment from high-profile organizations such as Microsoft, which has invested in the company's technology for use in molecular diagnostics.
Some of the diseases that Adaptive Biotechnologies is exploring include cancer, autoimmune disorders, infectious diseases, and neurodegenerative diseases.
The company is also involved in developing COVID-19 testing products and has partnered with Microsoft to develop a blood-based test that can identify the immune response to the virus.
Adaptive Biotechnologies has received recognition for its innovative technology and research.
In 2019, the company was named a Technology Pioneer by the World Economic Forum, which honors companies that are using technology to solve global issues.
In summary, Adaptive Biotechnologies Corporation is a leading biotechnology company focused on developing innovative immune-driven technologies to diagnose, manage, and treat various diseases.
The company's immune profiling technology, proprietary database, and partnerships with biopharmaceutical companies and academic institutions have made it a leader in the field of immune-driven medicine.


   Company Address: 1165 Eastlake Avenue East Seattle 98109 WA
   Company Phone Number: 659-0067   Stock Exchange / Ticker: NASDAQ ADPT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Illuminating the Future of Blood Cancer Care: Adaptive Biotechnologies' ClonoSEQ MRD Testing and Emerging Innovations

Published Tue, Dec 5 2023 12:31 PM UTC



In an era where personalized medicine is gaining traction, Adaptive Biotechnologies, a leader in immune-driven medicine, has been making significant strides. In collaboration with other industry partners, the company has presented more than 30 abstracts at the 65th ASH Annual Meeting, showcasing the actionability of clonoSEQ MRD testing in blood cancer patient care...

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp: Rising Above Losses, Paving the Way for Biotech Innovation



In the third quarter financial report of 2023, Adaptive Biotechnologies Corporation showcased a concerning trend of advancing losses. The company witnessed a net deficit per share rise from $-0.32 to $-0.35, corresponding to a 9.375% increase. Notably, revenue plummeted by a staggering -20.721% from $47.83 million to $37.92 million compared to the previous year. Furthermore, the Q2 revenue also endured a significant decline of -22.497%, dropping from $48.93 million and bringing attention to the surging deficit.
Financial Performance:
Adaptive Biotechnologies Corporation reported a net deficit of $-50.326 million for the most recent fiscal period, reflecting an increase from $-45.319 million in the same period a year ago. Such escalating losses, coupled with declining revenue, indicate a potential deterioration in the company's financial health.

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Reports Sector-Leading Revenue Growth Despite Dwindling Returns, Ending Fiscal Quarter Strong on June 30, 2023



Adaptive Biotechnologies Corporation, a prominent player in the Biotechnology & Pharmaceuticals sector, has experienced a decline in shares over the past five trading days. With a year-to-date performance of -22.56%, the company has been facing challenges. However, it is noteworthy that shares are still trading 1.3% above the 52-week low. Analyzing the recent financial results, it is essential to interpret how these figures may impact the company's future.
1. Earnings per Share Improvement:
For the fiscal quarter ending June 30, 2023, Adaptive Biotechnologies Corporation showcased positive progress in its earnings per share (EPS). The company recorded a loss per share of $-0.33, an improvement from $-0.37 compared to the previous year, indicating the company's efforts to reduce losses. This positive trend enhances investor confidence and suggests that Adaptive Biotechnologies is moving towards profitability.

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation defies market expectations with surprising outcomes in the fiscal period closing Mar 31, 2023

The stock market is a great way to invest your money and potentially earn a profit, but it can be tricky to navigate. There are so many different companies to choose from, and it can be difficult to know which ones will be successful and which ones will not. One company that has been making waves in the healthcare sector lately is Adaptive Biotechnologies Corporation.
Adaptive Biotechnologies Corporation has recently recorded a cumulative net loss of $-195 million during the 12 months ending in the first quarter of 2023, resulting in a negative return on investment (ROI) of -26.72%. While this may not sound like great news, there are definitely some bright spots to be found.






 

Adaptive Biotechnologies's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com